focus -WSS

focus

author：leisure time 2025-09-28 01:36:14 - browse：9839

Aduhelm package — Jessica Rinaldi/The Boston Globe

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history.

Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. Biogen will also terminate an ongoing clinical trial meant to prove the treatment’s benefits for patients in the early stages of Alzheimer’s.

“When searching for new medicines, one breakthrough can be the foundation that triggers future medicines to be developed,” Biogen CEO Christopher Viehbacher said in a statement. “Aduhelm was that groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the field.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Making the case for fair compensation in clinical trials

focus

hotspot

WSS

Philips to halt sales of sleep apnea machines in U.S.

Study finds gene variants tied to breast cancer risk in Black women

Digital health: a case of mistaken identity

Liver decline slowed by off

Health Care Service Corp to buy Cigna Medicare Advantage plans

FDA poised to publish guidelines for clinical trial diversity

hotspot

focus

explore

What does generative AI mean for health care? We asked experts

Why you shouldn’t ask, “What country has the best health care?”

How to save PrEP access — and even expand it

Zyn nicotine pouches become unlikely player in latest culture war

Heart attack and stroke risk calculators need revising

UnitedHealth argues against case alleging wrongful AI care denials

Novavax promises a turnaround & Lilly roils the obesity market

As a primary care physician, here's how I hope to partner with AI

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why Medicare shouldn’t cover every FDA

explore

At flashy new research hub, AstraZeneca lays out ambitious growth goals

H5N1 virus can be tracked in retail milk, scientists say

Reports of telehealth's death have been greatly exaggerated

Zyn nicotine pouches become unlikely player in latest culture war

Medicare drug price negotiation legal challenge met with skepticism

H5N1 virus can be tracked in retail milk, scientists say

focus

hotspot

focus

hotspot